Biomarker

In this video from the virtual European Society of Cataract and Refractive Surgeons meeting, Rohit Shetty, MD, PhD, speaks about biomarkers, a new dimension in understanding, predicting and preventing disease.

A composite type-2 biomarker corticosteroid adjustment strategy did not result in a greater proportion of patients with severe asthma reducing their corticosteroid dose, according to results published in The Lancet Respiratory Medicine.

For healthy patients, miR-34a may be a reliable biomarker to effectively rule-out nonalcoholic fatty liver disease, according to research presented at The Digital International Liver Congress.

Ketamine dose and blood level appeared closely related, and both were significantly associated with antidepressant benefit, according to results of a randomized clinical trial published in JAMA Network Open.

The release of findings from the Checkmate-214 study produced multiple changes for specialists in renal cell carcinoma. Chung-Han Lee, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, spoke with Healio about CheckMate-214 findings, clinical relevance, FDA approvals of TKI/IO regimens and possible novel agents.

Neutrophil to lymphocyte ratio may be a clinically relevant biomarker associated with increased risk for COPD and lung function impairment, according to data published in JAMA Network Open.

Telomere length may serve as a useful biomarker to predict risk for prevalent and incident cardiovascular complications among people with diabetes, according to findings published in Diabetes Care.

With new targeted and immune-based treatments coming out for renal cell carcinoma, predictive biomarkers are needed more than ever. The many different tumor entities of RCC, their genetic and mutational alterations and different clinical behaviors all contribute to a complex disease that requires personalized treatment.

Healio spoke with Fred R. Hirsch, MD, PhD, professor of medicine and pathology at the University of Colorado Cancer Center in Denver and CEO of the International Association for the Study of Lung Cancer, about the multiple clinical trials being performed in the United States and Europe that study biomarkers and personalized medicine in the field of lung cancer.

Despite the success of immunotherapy in the treatment of patients with advanced malignancies, responses in metastatic castration-resistant prostate cancer have been limited.